<DOC>
	<DOCNO>NCT01147991</DOCNO>
	<brief_summary>RATIONALE : Vaccines make gene-modified virus may help body build effective immune response kill tumor cell . PURPOSE : This phase I trial study side effect best dose vaccine therapy treat patient Epstein-Barr virus cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Epstein-Barr Virus-Related Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine safety characterize toxicity profile EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modify vaccinia Ankara vaccine patient remission treat conventionally Epstein-Barr virus ( EBV ) malignancy . - To describe change frequency functional T-cell response major histocompatibility complex ( MHC ) class I II-restricted epitope within EBNA1 LMP2 peripheral blood sequential time-points , , nine month vaccination course patient . Secondary - To assess change level EBV genome plasma patient . OUTLINE : This multicenter , dose-escalation study . Patients receive EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modify vaccinia Ankara vaccine intradermally day 1 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . Blood sample collect periodically immune function , biomarker , pharmacological study . After completion study treatment , patient follow week 11 14 , 6 month 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy type typically associate EpsteinBarr virus ( EBV ) latent infection meeting follow criterion : The presence EBV within malignant cell demonstrate immunohistochemistry viral antigen EBER ( EBV early RNA ) situ hybridization Patients remission disease disease standard treatment appropriate , define 1 follow group : Have achieve continue complete response ( CR ) unconfirmed CR Residual mass site treated disease progressing ( i.e. , stable disease ) standard therapy recognize Residual recurrent disease lowvolume cause minimal symptom standard therapy recognize Completed standard therapy malignancy ≥ 12 week trial entry No 1 course chemotherapy treatment EBV+ malignancy No ongoing toxic manifestation prior treatment , except alopecia certain grade 1 toxicity discretion investigator Cancer Research UK No patient active EBV+ cancer evidencebased active treatment available likely offer prolong life relieve symptom within 14 week first vaccination PATIENT CHARACTERISTICS : WHO performance status 0 1 Life expectancy ≥ 4 month Lymphocyte count must satisfy 1 follow criterion : Greater low limit reference range investigator site Greater equal 0.5 x 10^9/L AND recovery nadir lymphocyte number follow primary treatment EBV+ malignancy , judge successive rise lymphocyte count measure 3 successive occasion 3 week apart Hemoglobin &gt; 10.0 g/dL Absolute neutrophil count ≥ 1.5 x 10^9/L Platelet count ≥ 100 x 10^9/L Serum bilirubin ≤ 1.5 time upper limit normal ( ULN ) Serum alkaline phosphatase &lt; 1.5 time ULN ALT and/or AST &lt; 1.5 time ULN Calculated creatinine clearance &gt; 50 mL/min ( uncorrected value ) OR isotope clearance measurement &gt; 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception study 6 month completion study treatment No known chronic active infection hepatitis B , hepatitis C , HIV No history anaphylaxis severe allergy vaccination No allergy egg egg product No ongoing active infection No known splenic dysfunction No concurrent active autoimmune disease No prior NYHA class III IV cardiac disease concurrent congestive heart failure No concurrent active skin disease require therapy ( i.e. , psoriasis , eczema ) No condition , Investigator 's opinion , would make patient good candidate clinical trial PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior myeloablative therapy follow autologous allogeneic hematopoietic stem cell transplant More 12 week since prior concurrent chemotherapy radiotherapy No splenectomy splenic irradiation No concurrent immunosuppressive medication , include corticosteroid Longterm prophylactic use inhale corticosteroid allow No major thoracic and/or abdominal surgery within past 4 week patient yet recover No concurrent anticancer investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Epstein-Barr virus infection</keyword>
	<keyword>stage I nasopharyngeal cancer</keyword>
	<keyword>stage II nasopharyngeal cancer</keyword>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>stage I gastric cancer</keyword>
	<keyword>stage II gastric cancer</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
</DOC>